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ABSTRACT The type I DNA topoisomerases are targets
for a variety of chemotherapeutic agents, Includin the anti-
bacterial quinolones and several famile of antitumor drugs.
These agents stabilize an epzyme-DNA cleavage complex that
consists of the topoisomerase covalently linked to the 5' phos-
phates of a double-stranded DNA break. Although the drug-
stabilized cleavage complex is readily reversible, it can result in
cell death by a mechanism that remains uncertain. Here we
demonstrate that the action of a DNA helicase can convert the
cleavage complex into a nonreversible DNA break by displacing
DNA strands from the complex. Formation of a nonreversible
DNA break, induced by a DNA helicase, could explain the
cytotoxicity of these topoisomerase poisons.
Topoisomerases play a major role in cellular DNA metabo-
lism by altering the topological state of DNA. Type II DNA
topoisomerases effect this change by creating a transient
double-stranded DNA (dsDNA) break through which a sec-
ond DNA segment is passed (1-3). Several classes of chemo-
therapeutic drugs, including the acridines, anthracyclines,
ellipticines, and epipodophyllotoxins, inhibit the type II
topoisomerases (4, 5). These drugs stabilize a protein-DNA
complex, called the cleavage complex, in which the enzyme
is covalently linked to each 5' phosphate of a staggered
dsDNA break. Although both strands of the DNA helix are
thought to be broken, the linear integrity of the DNA is
maintained by a noncovalent topoisomerase bridge. The
simplest model is that the inhibitors trap the cleavage com-
plex by inhibiting the ligation step of the enzymatic cycle.
The type II topoisomerases are a primary cellular target for
many of the chemotherapeutic drugs described above. Stud-
ies on drug-resistant mammalian cell lines revealed alter-
ations in topoisomerase levels or activity, suggesting that the
enzyme is an important component of the cytotoxic response
(6, 7). Genetic studies in Saccharomyces cerevisiae have
demonstrated that a temperature-sensitive mutation in the
type II topoisomerase gene greatly decreased drug sensitivity
at the semipermissive temperature, presumably due to a
reduction in topoisomerase activity (8). Perhaps the clearest
evidence for a type II topoisomerase being the primary drug
target comes from the T4 bacteriophage system. The prop-
erties of the T4 topoisomerase closely resemble those of the
mammalian enzyme (1, 9). Most importantly, both are sen-
sitive to the aminoacridine m-AMSA [4'-(9-acridinylami-
no)methanesulfon-m-anisidide] (10, 11). A point mutation in
one of the genes encoding the bacteriophage T4 topoisom-
erase allows drug-resistant phage growth, and topoisomerase
purified from the mutant phage has drug-resistant topoisom-
erase activity (12, 13).
Topoisomerase inhibitors convert the enzymes that they
target into poisons by inducing formation of the cleavage
complex, a form of DNA damage. This view was first
articulated when it was found that bacteriophage 17 could be
inhibited by the quinolone nalidixic acid, even though phage
growth was not significantly reduced by mutational inacti-
vation of DNA gyrase (14). Importantly, mutational inacti-
vation of DNA gyrase protected 17 from inhibition by the
drug (14). More recent results imply that the cleavage com-
plex is critical for the cytotoxicity of antitumor agents that
inhibit topoisomerases. For example,. defects in DNA repair
have been shown to increase drug sensitivity (refs. 15-17;
S.H.N., K. Carles-Kinch, and K.N.K., unpublished data),
indicating that the topoisomerase inhibitors induce DNA
damage. In spite of the importance of the cleavage complex
in cytotoxicity, the complexes are reversible both in vitro and
in vivo. To explain this apparent paradox, it has been
proposed that an active mechanism, such as transcription or
replication, converts reversible cleavage complexes into non-
reversible cytotoxic DNA lesions (ref. 18; also see Discus-
sion).
We investigated whether helicase action could convert a
type II topoisomerase cleavage complex into a nonreversible
DNA break by examining the DNA products generated when
Escherichia coli helicase II unwinds a DNA substrate con-
taining an m-AMSA-induced T4 topoisomerase cleavage
complex. These two enzymes were selected for the following
reasons: (i) The bacteriophage T4 topoisomerase closely
resembles mammalian type II topoisomerases in reaction
mechanism and sensitivity to inhibitors (see above). (ii) A
strong m-AMSA-inducible T4 topoisomerase cleavage site
has been cloned near the middle of a 703-bp DNA fragment
(G. Hong and K.N.K., unpublished data), facilitating anal-
ysis of cleavage complexes occurring at a single site. The
sequence of this cleavage site was based on mutational
analyses of a T4 topoisomerase cleavage site and on exper-
iments with in vitro substrates containing optimal sequences
for DNA cleavage (ref. 19 and C. Freudenreich and K.N.K.,
unpublished data). (iii) Several topoisomerase inhibitors
have been shown to block helicase activity in vitro (20-23);
however, E. coli helicase II was found to be insensitive to
m-AMSA (20). (iv) Unlike most other DNA helicases, E. coli
helicase II does not require a single-stranded DNA (ssDNA)
loading site to initiate DNA strand separation (24). This
allows the use of fully duplex linear DNA substrates, which
is important because the T4 topoisomerase interacts strongly
with ssDNA and ssDNA-dsDNA junctions (25).
MATERIALS AND METHODS
DNA Substrate. The DNA substrate was prepared from a
pBR322-derived plasmid, pGH2, containing a 28-bp insert
between the unique BamHI and Sal I restriction sites. The
insert was designed based on the studies ofFreudenreich and
Kreuzer (19) to produce a very efficient m-AMSA-inducible
Abbreviations: dsDNA, double-stranded DNA; m-AMSA, 4'-(-acri-
dinylamino)methanesulfon-m-anisidide); ssDNA, single-stranded
DNA; ATP[yS], adenosine 5'-[(-thio]triphosphate.
12031
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
12032 Biochemistry: Howard et al.
topoisomerase cleavage site (insert sequence is 5'-AAGC-
TAAAGTTATATAACTTTATTCAAG-3'). The 703-bp frag-
ment was generated by cleaving pGH2 DNA with HindIII
and Nru I, filling in the recessed 3' end with the Klenow
fragment of DNA polymerase I (Boehringer Mannheim),
treating with calf intestinal phosphatase and proteinase K,
and purifying by electrophoresis through a nondenaturing 6%
polyacrylamide gel. The DNA fragment was electroeluted,
ethanol-precipitated, and stored at -700C. The substrate was
labeled at the 5' ends using T4 polynucleotide kinase and
[y-32P]ATP (Amersham). Labeling was followed by a 5-min
chase at 370C with 50 gM (unlabeled) ATP to provide
completely phosphorylated 5' ends. Restriction enzymes,
calf intestinal phosphatase, T4 polynucleotide kinase, and
proteinase K were from New England Biolabs.
T4 Topoisomerase and Helicase II Reactions. Except where
indicated, topoisomerase cleavage reaction mixtures (40 1ul)
contained 40 mM Tris-OAc (pH 7.8), 20 mM KOAc, 8 mM
Mg(OAc)2, 0.5 mM EDTA, 2.5 mM. ATP, 0.5 mM dithio-
threitol, bovine serum albumin (35 ,ug/ml), 5% (vol/vol)
glycerol, 12.5 ,uM m-AMSA (NSC 249992, provided by the
National Cancer Institute), -1 fmol of 5'-32P-end-labeled
703-bp DNA fragment (see below), and purified T4 type II
topoisomerase (9, 13) at a molar ratio of -20 topoisomerase
dimers per duplexDNA fragment. Controls lacking m-AMSA
received 0.02% (final concentration) dimethyl sulfoxide (m-
AMSA solvent) and those lacking enzyme received topo-
isomerase dilution buffer (9). Incubation was for 5 min at
320C.
Helicase II reactions were initiated by adding 2.8 pmol (1
,ul) of purified E. coli helicase 11 (26) to the cleavage com-
plexes above; helicase storage buffer was added to samples
that received no helicase. Incubation was then continued for
5 min at 32°C. After this incubation, either EDTA (50 mM,
final concentration) or SDS (1%, final concentration) was
added and incubation was continued for 20 min at 320C. All
samples were then adjusted to contain 50 mM EDTA and 1%
SDS and were treated with proteinase K (380 ug/ml) for 20
min at 37°C.
Gel Electrophoresis. Reaction products were resolved by
electrophoresis through polyacrylamide gels and visualized
by autoradiography. Denaturing gels contained 7 M urea and
6% polyacrylamide [acrylamide/N,N'-methylenebisacryl-
amide = 20:1 (wt/wt)], with lx TBE (89 mM Tris/89 mM
borate/2 mM EDTA) as running buffer; electrophoresis was
at 21-23 V/cm for -4 hr. Samples for the denaturing gels
consisted of 20-,l aliquots that were mixed with 15 Al of
loading solution [85% (vol/vol) formamide/lx TBE/0.1%
bromophenol blue/0.1% xylene cyanole] and heated for 5 min
at 1000C immediately before loading. Nondenaturing gels
contained 5% polyacrylamide, 0.1% SDS, and 25% glycerol,
with lx TBE containing 0.1% SDS as running buffer; elec-
trophoresis was at 4.4 V/cm for =21 hr. Samples for the
nondenaturing gels consisted of 20-,ul aliquots that were
mixed with 15 ,ul of loading solution (40o glycerol/50 mM
EDTA/0.5% SDS/0.02% bromophenol blue/0.02% xylene
cyanole). DNA markers (BioVentures, Murpheesboro, TN)
were labeled by incubation with T4 polynucleotide kinase and
[y-32P]ATP.
RESULTS
DNA Helicase II Prevents Reversal of m-AMSA-Induced T4
Topoisomerase Cleavage Complexes. Cleavage complexes
were established by incubating the T4 type II topoisomerase
with m-AMSA and the 703-bp 5'-end-labeled DNA substrate.
The DNA substrate contains a strong topoisomerase II
cleavage site located 337 bp from one end. The amount ofT4
topoisomerase cleavage complex was determined by stop-
ping the reactions with SDS, incubating with proteinase K,
and analyzing the products on polyacrylamide gels. Labeling
the DNA substrate at the 5' ends confines analysis to the
cleavage products that were not covalently linked to the
topoisomerase. An autoradiograph of a denaturing polyacryl-
amide gel revealed the two major products of cleavage at the
strong topoisomerase site along with bands generated from
minor topoisomerase cleavage sites (Fig. 1A, lanes 1 and 2).
To determine the impact of helicase activity on an
m-AMSA-induced cleavage complex, we used a cleavage
reversal assay in which the samples were exposed to EDTA
after the enzymatic reaction but prior to treatment with SDS
and proteinase K. This treatment causes reversal of cleavage
complexes formed by eukaryotic (27, 28), T4 (29), and E. coli
(30) type II topoisomerases. The mechanism of reversal is
unknown; however, the simplest explanation is that chelation
of magnesium prevents topoisomerase from initiating a new
round of cleavage but does not prevent DNA religation.
When EDTA was added to the topoisomerase reactions
without helicase, about 80% of the cleavage complexes at
both the major and minor sites were reversed (Fig. 1A, lanes
2 and 3). However, EDTA reversal was almost completely
blocked in reactions that contained helicase (Fig. 1A, lanes
4 and 5). The presence of the cleavage products was depen-
dent on m-AMSA (Fig. 1A, lanes 7 and 8) and topoisomerase
(Fig. 1A, lanes 9 and 10). Thus, reversible m-AMSA-induced
type II topoisomerase cleavage complexes were converted to
nonreversible DNA breaks by helicase II.
Aliquots of the same reactions were analyzed on a nonde-
naturing polyacrylamide gel to examine further the nature of
the cleavage products and determine the extent of helicase
unwinding. The addition of helicase to topoisomerase reac-
tions resulted in the appearance of several new bands (Fig.
1B, lanes 2 and 4). These bands comigrated with bands
produced when the helicase-free topoisomerase cleavage
reactions were subjected to heat denaturation prior to elec-
trophoresis (Fig. 1B, lane 6; note that one of the major
ssDNA cleavage products comigrates with one of the major
dsDNA cleavage products). Therefore, helicase II can un-
wind DNA cleavage complexes to yield ssDNA cleavage
products. Furthermore, the ssDNA cleavage products gen-
erated by topoisomerase plus helicase are not reversible by
EDTA treatment (Fig. 1B, lanes 4 and 5). Helicase II also
unwound the topoisomerase-free substrate DNA to generate
full-length ssDNA molecules that migrated slower than the
full-length duplex DNA (Fig. 1B, lanes 4, 5, and 7-10). Again,
the presence of cleavage products was strictly dependent on
m-AMSA (Fig. 1B, lanes 7 and 8) and topoisomerase (Fig.
1B, lanes 9 and 10). We conclude from this analysis that,
coincident with converting reversible cleavage complexes to
nonreversible DNA breaks, helicase II unwinds DNA con-
strained within the cleavage complex to produce ssDNA
cleavage products.
T4 topoisomerase can cleave ssDNA and form a covalent
protein-DNA complex that is resistant to reversal by EDTA
treatment (25). Therefore, an alternative interpretation
seemed possible: perhaps the nonreversible DNA breaks
analyzed in this study were due to formation of cleavage
complexes on the ssDNA product of the helicase II unwind-
ing reaction. To test this possibility, topoisomerase-induced
cleavage products were analyzed using the 703-bp DNA
substrate that had been heat-denatured immediately prior to
the topoisomerase reaction. Although cleavage sites were
detected on the ssDNA, the products did not comigrate with
the nonreversible topoisomerase cleavage products gener-
ated from dsDNA in the presence of helicase (Fig. 1C, lanes
5-7). In addition, the binding of helicase II to the heat-
denatured substrate inhibited the ssDNA cleavage by the T4
topoisomerase (Fig. 1C, lanes 7 and 9). Therefore, the
nonreversible cleavage complexes were not formed by the
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200 FIG. 2. Requirement for ATP hydrolysis and DNA unwinding by
helicase II. (A) The three stages of the reactions were the same as
those in Fig. 1 except that reaction mixtures 6-10 contained ATP[-S]
instead of ATP. All reaction mixtures contained m-AMSA. Reaction
products were analyzed on a nondenaturing 5% polyacrylamide/0.1%
SDS gel as described in Fig. 1. Samples S and 10 were heat-denatured
(100TC, 5 min) immediately before loading on the gel. (B) The three
stages of the reactions were the same as those in Fig. 1 except that
some samples were incubated with wild-type helicase II (wtHel II;
St lanes 4 and 5) and others with the K35M mutant helicase II (K35MHel
00 II; lanes 6 and 7; same concentration as the wtHel II). All reactions
contained m-AMSA. Reaction products were analyzed on a nonde-
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FIG. 1. Effect of E. coli helicase II on the T4 topoisomerase
cleavage reaction. In the first stage of the reactions, the 5'-32P-end-
labeled DNA substrate was incubated for 5 min at 32°C with (+) or
without (-) T4 type II topoisomerase (Topo) and m-AMSA. The
703-bp substrate contains a strong m-AMSA-inducible cleavage site
337 bp from one end. In the second stage of the reactions, E. coli
helicase II (Hel II) was added to some reactions (+), but not others
(-), and incubation was continued for 5 min at 32TC. In the third
action of topoisomerase on the ssDNA products of helicase
II unwinding.
The Effect of DNA Helicase H on m-AMSA-Induced Cleav-
age Complexes Is Dependent on ATP Hydrolysis. We next
investigated whether the generation of a nonreversible DNA
stage, either EDTA (+) or SDS (-) was added, and incubation was
continued for 20 min at 32TC. After the third stage, all samples were
adjusted to contain the same final concentrations ofEDTA and SDS,
respectively. Samples were then treated with proteinase K and
subjected to electrophoresis on a denaturing6% polyacrylamide/7M
urea gel (A) and on a nondenaturing 5% polyacrylamide gel (B). All
samples inA and samples 6 and 11 in B were heat-denatured (100TC,
5 min) immediately before loading on the gel. In C, the DNA
substrate in samples 7-10 was heat-denatured immediately prior to
the topoisomerase reaction and samples were subjected to electro-
phoresis on a denaturing gel as in A. Sample 6 in C is composed of
a mixture of samples identical to samples 5 and 7. Samples 9 and 10
in C had helicase added in the first stage of the reactions and
topoisomerase added in the second stage. DNA markers (M), with
sizes in nucleotides, are in lanes 12 ofA andB; the sizes and positions
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break by helicase II was dependent on the unwinding activity
of the enzyme. In the first approach, topoisomerase cleavage
reactions were performed in the presence of ATP or adeno-
sine 5'-[thio]triphosphate (ATP[yS]), a poorly hydrolyzed
analogue of ATP. T4 topoisomerase cleavage products are
formed with nearly equal efficiency in the presence of ATP
or ATP[yS] (S.H.N. and K.N.K., unpublished data; Fig. 2A,
compare lanes 1 and 6); however, unlike ATP, ATP[-yS]
cannot support the unwinding reaction catalyzed by helicase
11 (31). It should also be noted that ATP[yS] is a competitive
inhibitor ofthe ATP hydrolysis reaction catalyzed by helicase
II and should, therefore, bind at the active site of the enzyme.
As indicated previously, the cleavage complexes are resistant
to reversal when they are exposed to helicase II in the
presence of ATP (Fig. 2A, lanes 3 and 4). In contrast, the
reactions that were exposed to helicase II in the presence of
ATP[yS] were readily reversible (Fig. 2A, lanes 8 and 9),
indicating that the impact of helicase II on the cleavage
complex is dependent on ATP hydrolysis by helicase II. In a
second approach, we tested the K35M mutant helicase II,
which contains a single amino acid substitution rendering the
enzyme unable to hydrolyze ATP or unwind duplex DNA
(32). The complexes exposed to the mutant enzyme, in the
presence ofATP, were readily reversed (Fig. 2B, lanes 6 and
7). Finally, the effect of increasing concentrations of helicase
II on the reversibility of the cleavage complexes was exam-
ined. This analysis revealed roughly a direct correlation
between the total amount ofDNA unwound and the quantity
of nonreversible cleavage products (data not shown). Thus,
these results strongly argue that ATP hydrolysis and DNA
unwinding are necessary to convert reversible cleavage prod-
ucts to nonreversible DNA breaks.
DNA Helicase I Can Disrupt an m-AMSA-Induced Cleavage
Complex in the Absence of Protein Denaturation. While DNA
within the cleavage complex is thought to be cleaved, the
continuity ofthe DNA duplex is maintained by a noncovalent
topoisomerase bridge. The DNA break is generally observed
only when the cleavage complex is treated with a protein
denaturant (e.g., SDS) that disrupts the topoisomerase bridge
(2, 3). In all of the above experiments, the products were
treated with SDS and proteinase K. One could argue that
unwinding the DNA around the cleavage complex alters the
complex without disrupting it, so that it cannot be reversed.
In this model, cleaved DNA products are not released until
treatment with SDS and proteinase K. However, if helicase
II actually disrupts the cleavage complex, then DNA cleav-
age products should be detectable without protein denatur-
ation. To distinguish between these alternatives, we analyzed
reaction products directly on a nondenaturing gel without
SDS or proteinase K treatment (Fig. 3, lanes 1-6). Indeed,
cleavage products were observed in a reaction that was
strictly dependent on helicase II (Fig. 3, lane 3). These
cleavage products were further analyzed by including a mild
heat treatment (65°C) prior to electrophoresis, which releases
helicase II from the ssDNA (M.T.H. and S.W.M., unpub-
lished data). Because the DNA substrate is labeled at the 5'
ends, the cleavage products that are covalently linked to T4
topoisomerase are not detected in this analysis. After being
released from helicase II, the cleavage products observed in
the absence of SDS and proteinase K (Fig. 3, lane 4)
comigrated with topoisomerase cleavage products that had
been treated with SDS and proteinase K and then heat-
denatured at 100°C (Fig. 3, lane 7). We conclude that helicase
II can displace ssDNA from the cleavage complex in a
reaction that is independent of protein denaturation or heat
treatment. These results also provide compelling evidence
for the prevalent view that the DNA within the topoisomer-
ase cleavage complex is cleaved, even without protein de-
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FIG. 3. Release of ssDNA fragments from topoisomerase cleav-
age complexes. The first two stages of the reactions were the same
as those in Fig. 1. All reactions contained m-AMSA. After the second
stage some of the reactions were heat-treated for 20 min at 65TC (+)
and others were not (-). Only the reaction products in lanes 7-11
were treated with SDS and proteinase K (Prot K). Reaction products
were analyzed on a nondenaturing 5% polyacrylamide gel as de-
scribed in Fig. 1, except that the gel and the running buffer lacked
SDS and reaction mixtures with no SDS were chilled and loaded on
the gel in a glycerol/dye solution containing no SDS. After treatment
with SDS and proteinase K, sample 7 was extracted with phenol and
passed through a Sepharose CL-6B spin column, and samples 6 and
7 were heat-denatured (100TC, 5 min) immediately before loading on
the gel.
DNA cleavage is induced by the protein denaturation step
(refs. 30 and 33; also see refs. 28 and 34).
The results in Fig. 3 also provide an independent confir-
mation of the nonreversibility of DNA breaks induced by
helicase II. The 65TC treatment resulted in reversal of topo-
isomerase cleavage complexes in the absence, but not in the
presence, of helicase II (Fig. 3, lanes 8-11).
DISCUSSION
To explain the cytotoxicity of drug-induced cleavage com-
plexes, it has been argued that a cellular process, such as
replication or transcription, converts the reversible cleavage
complexes into permanent cytotoxic DNA lesions (18). The
role of replication and transcription in the cellular response
to topoisomerase inhibitors has been previously investigated
by measuring drug cytotoxicity under conditions where DNA
or RNA synthesis is inhibited (35-37). Transcription inhibi-
tors had little effect on the cytotoxicity of type I topoisom-
erase inhibitors, but partially protected cells treated with
inhibitors of type II topoisomerases (37). In addition, the
DNA synthesis inhibitor aphidocolin abrogated the cytotox-
icity of inhibitors targeting type I and type II topoisomerases
(36, 37). Recent studies in a cell-free simian virus 40 repli-
cation system provided evidence that camptothecin-induced
type I topoisomerase cleavage complexes arrest replication
forks and lead to dsDNA breaks (38).
Helicase-driven separation of the double helix occurs
duringDNA replication and also during otherDNA metabolic
activities such as repair and recombination (39, 40). There-
fore, we sought to determine whether helicase action on
DNA containing a type II topoisomerase cleavage complex
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Proc. Natl. Acad. Sci. USA 91 (1994) 12035
3' -- i = 3'
3 51
FiG. 4. Model for disruption of a topoisomerase cleavage com-
plex byDNA helicase II. Steps: I, initiation ofunwinding by helicase
II on the DNA of an m-AMSA-induced topoisomerase-DNA cleav-
age complex; II, encounter of helicase H with the topoisomerase
cleavage complex; Ill, release ofa ssDNA cleavage product from the
complex, with one of the possible remaining products shown.
could create a DNA lesion by displacing broken DNA from
the complex. The generation of such a DNA lesion would be
a plausible step in the pathway that generates a cytotoxic
response to topoisomerase inhibitors.
The data presented in this paper provide biochemical
evidence that DNA helicases can indeed convert drug-
induced type II topoisomerase cleavage complexes to irre-
versible DNA lesions. We have shown that E. coli DNA
helicase II converts a T4 topoisomerase cleavage complex
into a DNA break that cannot be reversed by either EDTA
or heat treatment. Furthermore, helicase II disruption of
topoisomerase-DNA cleavage complexes releases cleaved
ssDNA fragments in a reaction that requires ATP hydro-
lysis (Fig. 4).
Although E. coli helicase II disrupts cleavage complexes in
vitro, we believe that a T4-encoded helicase is more likely to
play a physiological role in disrupting T4 topoisomerase
cleavage complexes during a phage infection in vivo. None-
theless, the results presented here confirm the general prem-
ise that DNA helicases can disrupt topoisomerase cleavage
complexes.
DNA helicases may also play a role in various recombi-
nation and/or mutation events induced by DNA topo-
isomerases. Topoisomerase inhibitors that induce the cleav-
age complex have been shown to stimulate homologous
recombination, sister chromatid exchange, gross genetic
rearrangements, and frameshift mutations at sites of cleavage
complex formation (4, 18, 41). For each of these genetic
events, the helicase-mediated generation of discrete DNA
breaks from a cleavage complex would be a reasonable first
step.
DNA helicases have recently been found to be sensitive to
certain topoisomerase inhibitors, and each helicase appears
to have its own unique spectrum of sensitivity (20-23). If a
DNA helicase converts the topoisomerase cleavage complex
into a cytotoxic lesion in vivo, then topoisomerase inhibitors
that do not inhibit the helicase should be more cytotoxic than
those that do.
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